Dr. Reddy’s & Integra LifeSciences Enter into an Agreement to Market & Distribute DuraGen Plus® & Suturable DuraGen® Dura...
March 27 2017 - 5:04AM
Business Wire
Dr. Reddy's Laboratories Limited (BSE:500124, NSE:DRREDDY,
NYSE:RDY) and Integra LifeSciences Holdings Corporation (NASDAQ:
IART), a leading global medical technology company, announced today
that they have entered into an exclusive distribution agreement.
Under the agreement, Dr. Reddy’s will market and distribute DuraGen
Plus® and Suturable DuraGen® Dural Regeneration Matrices for use in
patients in India.
M. V. Ramana, Executive Vice President and Head of Emerging
Markets & India Business, Dr. Reddy’s Laboratories said, “We
are delighted to partner with Integra LifeSciences. With the launch
of DuraGen, we look forward to building our presence in the segment
of regenerative technologies and making a difference to the lives
of patients undergoing neurosurgery.”
“Our market-leading DuraGen products have helped more than one
million patients worldwide,” said Glenn Coleman, Chief Financial
Officer and Corporate Vice President, International, Integra
LifeSciences. “This collaboration will allow us to continue to
expand patient access globally and provide innovative regenerative
technology solutions to neurosurgeons and patients in India.”
The DuraGen product line offers Duraplasty Solutions™ meant for
the repair of the dura mater. Dura mater is a
thick membrane that surrounds
the brain and spinal cord, and contains the
cerebrospinal fluid (CSF). DuraGen Plus Dural Regeneration Matrix
is indicated as a dural substitute for the repair of dura mater. It
offers a simple technique for precise placement of the matrix as an
onlay graft in cranial and spinal procedures, and easily conforms
to the complex surfaces of exposed neural tissue. It provides
effective protection against CSF leakage with sutureless closure
and is fully resorbed and replaced by native tissue with complete
dural closure.
Suturable DuraGen matrix is a versatile graft that can be
sutured and is designed for repairing dural defects where
mechanical anchoring of the graft is preferred. This offers
excellent suture retention with all the benefits of DuraGen Plus
Matrix.
Integra's DuraGen products have been implanted in more than 1.8
million patients worldwide to effect dural closure following
neurosurgical procedures. Integra manufactures the DuraGen family
of products based on its proprietary Ultra Pure Collagen™
technology platform.
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy’s offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy’s operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and Europe. For more information, log
on to: www.drreddys.com.
About Integra LifeSciences Corporation: Integra
LifeSciences Holdings Corporation, a world leader in medical
technology, is dedicated to limiting uncertainty for clinicians, so
they can concentrate on providing the best patient care. Integra
offers innovative solutions, including leading plastic and
regenerative technologies, in specialty surgical solutions,
orthopedics and tissue technologies. For more information, please
visit www.integralife.com.
Disclaimer: This press release may include statements of
future expectations and other forward-looking statements that are
based on the management’s current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual
results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements
which are forward-looking by reason of context, the words "may,"
"will," "should," "expects," "plans," "intends," "anticipates,"
"believes," "estimates," "predicts," "potential," or "continue" and
similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in
such statements due to without limitation, (i) general economic
conditions such as performance of financial markets, credit
defaults, currency exchange rates, interest rates, persistency
levels and frequency/severity of insured loss events (ii) mortality
and morbidity levels and trends, (iii) changing levels of
competition and general competitive factors, (iv) changes in laws
and regulations and in the policies of central banks and/or
governments, (v) the impact of acquisitions or reorganization,
including related integration issues.
The company assumes no obligation to update any information
contained herein.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170327005418/en/
Dr. Reddy’s Laboratories Ltd.INVESTOR RELATIONSSAUNAK
SAVLA, +91-40- 49002135saunaks@drreddys.comorMEDIA
RELATIONSCALVIN PRINTER, +91-40-
49002121calvinprinter@drreddys.com
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024